Simba Gill - 08 Jun 2023 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
President & CEO, Director
Signature
/s/ Marella Thorell, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.
Issuer symbol
EVLO on OTC
Transactions as of
08 Jun 2023
Net transactions value
$0
Form type
4
Filing time
12 Jun 2023, 16:01:55 UTC
Previous filing
10 May 2023
Next filing
22 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +1,000,000 $0.000000 1,000,000 08 Jun 2023 Common Stock 1,000,000 $0.9700 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Om March 17, 2023, the reporting person was granted an option to purchase 1,000,000 shares of the issuer's common stock subject to certain conditions, including the approval of the amendment and restatement of the Evelo Biosciences, Inc. 2018 Incentive Award Plan (the "2018 Plan") by stockholders at the issuer's 2023 Annual Meeting of Stockholders. The stockholders approved the amendment and restatement of the 2018 Plan on June 8, 2023.
F2 The option vests in forty-eight (48) substantially equal installments at the end of each monthly anniversary of February 7, 2023, subject to the reporting person's continued service to the issuer on each such vesting date.

Remarks:

Exhibit 24: Power of Attorney